Progentos Therapeutics, a Watertown, MA-based biotech firm addressing the necessity to regenerate myelin and restore operate for sufferers with A number of Sclerosis (MS) and different demyelinating ailments, closed a $65m sequence A funding spherical.
The spherical was led by Forbion which was joined by Alta Companions, Mission BioCapital, Longwood Fund, and Dolby Household Ventures.
This funding will allow the corporate to advance its MS program by way of human proof of idea research and increase its pipeline in extra degenerative ailments.
Led by Dr. Chris Free, CEO, Progentos is creating first-in-class small molecules designed to induce remyelination of axons affected by MS. In MS, incapacity is brought on by demyelination, harm to the myelin sheaths that assist the operate and survival of axons. The corporate’s proprietary molecules outperform earlier approaches in differentiating oligodendrocyte progenitor cells (OPCs) to generate new oligodendrocytes and regenerate myelin in in vivo fashions.
Progentos may have operations in Watertown, MA, USA and Naarden, The Netherlands.
FinSMEs
20/05/2024
